DNLI News and Press, Denali Therapeutics Inc. From 06/02/19

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...

Denali Therapeutics (NASDAQ: DNLI ): Q1 GAAP EPS of -$0.41 misses by $0.02 . Revenue of $4.2M (+556.3% Y/Y) beats by $1.22M . Press Release More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

Gainers: PHAS   +31.6% . GWPH   +4.1% . RUHN   +2.9% . IGC   +1.9% . SENS   +1.9% . More news on: PhaseBio Pharmaceuticals, Inc., GW Pharmaceuticals plc, Hangzhou Ruhnn Holding Co.,Ltd, Stocks on the move, Read more ...

Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa...

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...

SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended...

Dosing is underway in a Phase 1b clinical trial evaluating Denali Therapeutics' (NASDAQ: DNLI ) DNL747 in Alzheimer's disease patients. The primary objectives are safety and biomarker data which will inform future studies. More news on: Denali Therapeutics, Inc., Sanofi, Healthcare st...